Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
NEW YORK, NY, September 10, 2025 – Royalty Pharma plc today announced the release of a biopharma royalty market study conducted by Deloitte.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
16
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$2.8bn
Portfolio Receipts
(2024)
(2024)
$2.6bn
Adjusted EBITDA
(2024)
(2024)
$2.4bn
Average annual capital deployed (2019-2024)
$2.8bn
Announced value of transactions (2024)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q2 2025
Corporate presentation
Latest releases
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW YORK, NY, September 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
NEW YORK, NY, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)...
Royalty Pharma and Zenas Biopharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
NEW YORK, NY, and WALTHAM, MA, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.
